Back to News
Market Impact: 0.2
Leerink Partners Initiates Coverage of Nektar Therapeutics at Outperform
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
On October 12, 2026, Leerink Partners initiated coverage of Nektar Therapeutics with an Outperform recommendation, while UBS initiated coverage the same day with a Neutral rating. The article reports two same-day initiations and provides no price target, financial figures, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment
NKTR0.40
UBS0.00
More News
- UBS initiates TechnipFMC stock with buy rating on subsea growth
- Citizens initiates Orion180 Insurance stock with outperform rating
- UBS raises Wise price target 12% to 1,300p ahead of results
- We're upgrading our Goldman Sachs rating after a strong quarter bodes well for the future
- We're upgrading our rating on Wells Fargo as the stock's pullback offers a nice entry point
- Talos Energy 10% owner sells $106.8m in shares
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?
- Earnings-Triggered Research Automations: A Control Guide